Andrew Bascand, Managing Director of Harbour Asset Management joins me to discuss new findings of the GLP-1 drug class, which has predominantly been used to treat type 2 diabetes but has captured notable mindshare with healthcare specialists and macro investors.
Listen in for your chance to get ahead of the markets.
LISTEN ABOVE

Shane Solly: Spots of recovery in the economy
41:29

Janet Xuccoa: Where do trusts fit in to aged care funding?
41:20

Sharon Chandra: You could be essentially married without even realising it
40:48